User profiles for H. Kaufman

Howard Kaufman

- Verified email at mgh.harvard.edu - Cited by 31389

Howard S. Kaufman

- Verified email at hmri.org - Cited by 8264

Harvey Kaufman

- Verified email at questdiagnostics.com - Cited by 3982

[HTML][HTML] Oncolytic viruses: a new class of immunotherapy drugs

HL Kaufman, FJ Kohlhapp, A Zloza - Nature reviews Drug discovery, 2015 - nature.com
… Parvovirus H-1PV has been used in clinical trials of glioblastoma multiforme (GBM) 33 .
However, there have been relatively few studies of oncolytic virus distribution in vivo to evaluate …

[HTML][HTML] Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

…, T Illidge, M Karin, HL Kaufman… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune
response associated with immunological memory, provided they display sufficient …

Physics of closed drift thrusters

VV Zhurin, HR Kaufman… - Plasma Sources Science …, 1999 - iopscience.iop.org
Closed drift thrusters are reviewed. The publications on these thrusters constitute a large
body of information. This article can therefore include only the most prominent theoretical and …

[BOOK][B] Stabilizing an unstable economy

HP Minsky, H Kaufman - 2008 - filosofiadeldebito.it
4 INTRODUCTION affect the behavior of the system can be perceived only within a theory that
allows money and finance to affect what happens. Unfortunately, the economic theory that …

[HTML][HTML] Talimogene laherparepvec improves durable response rate in patients with advanced melanoma

RHI Andtbacka, HL Kaufman, F Collichio… - Journal of clinical …, 2015 - iro.uiowa.edu
Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-derived oncolytic
immunotherapy designed to selectively replicate within tumors and produce granulocyte …

[BOOK][B] The forest ranger: A study in administrative behavior

H Kaufman - 2010 - taylorfrancis.com
… I opened it, and in just the first few pages Kaufman showed me what I had not understood
before … Kaufman’s question was how an agency that was scattered among 792 administrative …

[HTML][HTML] Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity …

…, Y Wang, K Wiley, HL Kaufman… - … for immunotherapy of …, 2017 - Springer
… step, the FDA recently approved both pembrolizumab and nivolumab for use in certain
patients with mismatch repair deficient (dMMR) and microsatellite instability high (MSI-H) cancers …

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

HL Kaufman, J Russell, O Hamid, S Bhatia… - The lancet …, 2016 - thelancet.com
Background Merkel cell carcinoma is a rare, aggressive skin cancer with poor prognosis in
patients with advanced disease. Current standard care uses various cytotoxic chemotherapy …

[HTML][HTML] gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

…, J Balkissoon, DS Reintgen, H Kaufman… - … England Journal of …, 2011 - Mass Medical Soc
Background Stimulating an immune response against cancer with the use of vaccines remains
a challenge. We hypothesized that combining a melanoma vaccine with interleukin-2, an …

One hundred and forty-five consecutive pancreaticoduodenectomies without mortality.

…, HA Pitt, CJ Yeo, KD Lillemoe, HS Kaufman… - Annals of …, 1993 - ncbi.nlm.nih.gov
OBJECTIVE: A review of mortality and morbidity for pancreaticoduodenectomy was performed
for 145 consecutive patients who underwent the operative procedure between 1988 and …